NCT07495735 Intelligence System for Predicting Atezolizumab-Bevacizumab Response and Clinical Outcomes in Unresectable Hepatocellular Carcinoma
| NCT ID | NCT07495735 |
| Status | Recruiting |
| Phase | — |
| Sponsor | First Affiliated Hospital of Wenzhou Medical University |
| Condition | HCC - Hepatocellular Carcinoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 400 participants |
| Start Date | 2026-03-22 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 400 participants in total. It began in 2026-03-22 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a multicenter retrospective clinical research, led by the First Affiliated Hospital of Wenzhou Medical University, and jointly conducted by other sub-centers. The aim is to develop an non-invasive artificial intelligence system for predicting the response and clinical outcomes of patients with unresectable hepatocellular carcinoma (uHCC) to the treatment with atezolizumab combined with bevacizumab (T+A). In response to the clinical situation where approximately half of uHCC patients do not respond to the standard T+A therapy and traditional invasive biopsy is unable to fully reflect the heterogeneity of the tumor microenvironment, this study plans to retrospectively collect the data of 400 patients who met the inclusion and exclusion criteria from January 2020 to November 2025. The study will systematically summarize multi-dimensional data such as enhanced CT images within one month before treatment, baseline characteristics, serum markers, liver disease factors, and tumor stage. By integrating these clinical features with deep learning imageomics features extracted from images, the research team is dedicated to constructing and validating a safe, non-invasive, and reproducible prediction model, with the aim of achieving precise identification of the benefit population before implementing immunotherapy combined with anti-angiogenic treatment, and providing a powerful intelligent tool support for optimizing clinical treatment decisions and improving patient survival prognosis.
Eligibility Criteria
Inclusion Criteria: * (i) Clinical or pathological diagnosis of HCC; * (ii) Administration of atezolizumab-bevacizumab treatment; * (iii) At least 18 years old. Exclusion Criteria: * (i) Lack of key clinical data (laboratory test results), or lack of enhanced CT images taken within one month before treatment; * (ii) Comorbid with other malignant tumors; * (iii) PS score \> 2 or Child-Pugh score \> 7; * (iv) Unable to evaluate tumor response; * (v) Loss to follow-up.
Frequently Asked Questions
Who can join the NCT07495735 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying HCC - Hepatocellular Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07495735 currently recruiting?
Yes, NCT07495735 is actively recruiting participants. Visit ClinicalTrials.gov or contact First Affiliated Hospital of Wenzhou Medical University to inquire about joining.
Where is the NCT07495735 trial being conducted?
This trial is being conducted at Wenzhou, China.
Who is sponsoring the NCT07495735 clinical trial?
NCT07495735 is sponsored by First Affiliated Hospital of Wenzhou Medical University. The trial plans to enroll 400 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.